Global ETD Search

1	Reduced Burst Release of Bioactive rhBMP-2 from a Three-phase Composite Scaffold Grant, David William 31 December 2010 (has links) Recombinant human bone morphogenic proteins (rhBMPs) are extensively studied and employed clinically for treatment of various bone defects. Current clinical delivery vehicles suffer wasteful burst releases that mandate supra-physiological dosing driving concerns over safety and cost. It was therefore investigated whether a unique drug delivery vehicle sequestered within a composite scaffold could lower the burst release of rhBMP-2. PLGA-calcium phosphate tri-phasic composite scaffolds delivered model protein BSA with burst release of ~13% and sustained kinetics of 0.5-1.5% BSA/day up to 45 days. rhBMP-2 was delivered with zero burst release however at much lower levels, totaling 0.09% to 0.9 % release over 10 days, but had up to 6.3-fold greater bioactivity than fresh rhBMP-2 (p<0.05). In conclusion, the three-phase composite scaffold can deliver bioactive proteins with a reduced burst release and sustained secondary kinetics. Drug delivery Bone Bone morphogenic protein BMP BMP-2 rhBMP-2 bone graft tissue engineering scaffold bone tissue engineering regenerative medicine osteoinduction osteoconduction osteogenesis generative surgery autoraft replacement synthetic autograft replacement morphogenic bioactivity assay protein release kinetics bovine serum albumin model protein biomaterials biomaterial surface analysis scanning electron microscope application accelerating voltage application burst release sustained kinetics sustained delivery composite scaffold three phase scaffold PLGA calcium phosphate mineral-polymer composite sterilization BMP sterilization long-term storage BMP storage 0541
2	Reduced Burst Release of Bioactive rhBMP-2 from a Three-phase Composite Scaffold Grant, David William 31 December 2010 (has links) Recombinant human bone morphogenic proteins (rhBMPs) are extensively studied and employed clinically for treatment of various bone defects. Current clinical delivery vehicles suffer wasteful burst releases that mandate supra-physiological dosing driving concerns over safety and cost. It was therefore investigated whether a unique drug delivery vehicle sequestered within a composite scaffold could lower the burst release of rhBMP-2. PLGA-calcium phosphate tri-phasic composite scaffolds delivered model protein BSA with burst release of ~13% and sustained kinetics of 0.5-1.5% BSA/day up to 45 days. rhBMP-2 was delivered with zero burst release however at much lower levels, totaling 0.09% to 0.9 % release over 10 days, but had up to 6.3-fold greater bioactivity than fresh rhBMP-2 (p<0.05). In conclusion, the three-phase composite scaffold can deliver bioactive proteins with a reduced burst release and sustained secondary kinetics. Drug delivery Bone Bone morphogenic protein BMP BMP-2 rhBMP-2 bone graft tissue engineering scaffold bone tissue engineering regenerative medicine osteoinduction osteoconduction osteogenesis generative surgery autoraft replacement synthetic autograft replacement morphogenic bioactivity assay protein release kinetics bovine serum albumin model protein biomaterials biomaterial surface analysis scanning electron microscope application accelerating voltage application burst release sustained kinetics sustained delivery composite scaffold three phase scaffold PLGA calcium phosphate mineral-polymer composite sterilization BMP sterilization long-term storage BMP storage 0541

Search results

Reduced Burst Release of Bioactive rhBMP-2 from a Three-phase Composite Scaffold

Reduced Burst Release of Bioactive rhBMP-2 from a Three-phase Composite Scaffold